Polyfunctional Cytomegalovirus-Specific Immunity in Lung Transplant Recipients Receiving Valganciclovir Prophylaxis

被引:28
作者
Snyder, L. D. [1 ]
Medinas, R. [2 ]
Chan, C. [3 ]
Sparks, S. [2 ]
Davis, W. A. [1 ]
Palmer, S. M. [1 ]
Weinhold, K. J. [2 ]
机构
[1] Duke Univ, Dept Med, Durham, NC 27710 USA
[2] Duke Univ, Dept Surg & Immunol, Durham, NC USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
基金
美国国家卫生研究院;
关键词
Cytomegalovirus; lung transplantation; valganciclovir; T-CELL RESPONSES; RENAL-TRANSPLANTATION; CMV DISEASE; INFECTION; PROTECTION; RISK; IE-1;
D O I
10.1111/j.1600-6143.2010.03405.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Cytomegalovirus (CMV) is a common opportunistic infection after lung transplant. Despite effective antiviral medications to treat CMV, invasive CMV disease contributes to lung allograft dysfunction and worse survival. Efforts to prevent CMV have led to the use of valganciclovir prophylaxis for increasingly longer periods after transplant. A pivotal concern with long-term antiviral prophylaxis is that it may prevent or delay the development of CMV-specific immunity and increase the subsequent risk of late onset disease. To address this issue, we conducted a pilot study to determine if CMV-specific immunity was detectable in lung transplant recipients at risk for CMV while on antiviral prophylaxis. Utilizing polychromatic flow cytometry panels, CMV-specific immunity was determined by peripheral blood CD4 and CD8 T cell expression of cytokines in response to the HLA restricted CMV peptides pp65 and IE-1. We determined CMV seropositive lung transplant recipients on valganciclovir for a median of 6 months from transplant have a detectable polyfunctional CMV-specific T cell response which is comparable to seropositive recipients not on antiviral medications and to healthy seropositive nontransplant controls. Thus, valganciclovir prophylaxis does not appear to impair the development of CMV-specific immunity in lung transplantation.
引用
收藏
页码:553 / 560
页数:8
相关论文
共 50 条
[41]   Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients [J].
Reischig, Tomas ;
Prucha, Miroslav ;
Sedlackova, Lenka ;
Lysak, Daniel ;
Jindra, Pavel ;
Bouda, Mirko ;
Matejovic, Martin .
ANTIVIRAL THERAPY, 2011, 16 (08) :1227-1235
[42]   Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell Transplant Recipients [J].
Ugarte-Torres, Alejandra ;
Hoegh-Petersen, Mette ;
Liu, Yiping ;
Zhou, Feng ;
Williamson, Tyler S. ;
Quinlan, Diana ;
Sy, Sarah ;
Roa, Lina ;
Khan, Faisal ;
Fonseca, Kevin ;
Russell, James A. ;
Storek, Jan .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (04) :574-585
[43]   A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient [J].
Katada, Yoshiki ;
Umemura, Keisuke ;
Nakagawa, Shunsaku ;
Katsube, Yurie ;
Tsuda, Masahiro ;
Tanaka, Satona ;
Date, Hiroshi ;
Nagao, Miki ;
Terada, Tomohiro .
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01)
[44]   Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients [J].
Weclawiak, Hugo ;
Kamar, Nassim ;
Mengelle, Catherine ;
Guitard, Joelle ;
Esposito, Laure ;
Lavayssiere, Laurence ;
Cointault, Olivier ;
Ribes, David ;
Rostaing, Lionel .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (07) :1228-1232
[45]   Changes in cytomegalovirus-specific T-cell immunity with immunomodulation in serodiscordant high-risk transplant recipients [J].
Tinkham, Tyler ;
Song, Chelsey Chenxi ;
Winstead, Ryan ;
Yakubu, Idris ;
Brown, Andrew ;
Sterling, Sara ;
Gupta, Gaurav ;
Kumar, Dhiren .
TRANSPLANT INFECTIOUS DISEASE, 2021,
[46]   Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune Globulin [J].
Gutiérrez, CA ;
Chaparro, C ;
Krajden, M ;
Winton, T ;
Kesten, S .
CHEST, 1998, 113 (04) :924-932
[47]   Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis [J].
Helantera, I. ;
Kyllonen, L. ;
Lautenschlager, I. ;
Salmela, K. ;
Koskinen, P. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (09) :2026-2032
[48]   Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients [J].
Bixby, Alexandra L. ;
Fitzgerald, Linda ;
Park, Jeong M. ;
Kaul, Daniel ;
Tischer, Sarah .
TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
[49]   Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients [J].
Wreghitt, TG ;
Abel, SJC ;
McNeil, K ;
Parameshwar, J ;
Stewart, S ;
Cary, N .
TRANSPLANT INTERNATIONAL, 1999, 12 (04) :254-260
[50]   A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients [J].
Reischig, Tomas ;
Vlas, Tomas ;
Kacer, Martin ;
Pivovarcikova, Kristyna ;
Lysak, Daniel ;
Nemcova, Jana ;
Drenko, Petr ;
Machova, Jana ;
Bouda, Mirko ;
Sedivcova, Monika ;
Kormunda, Stanislav .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (05) :920-934